LadRx Corporation (LADX)
USD 1.49
(-2.61%)
USD 1.49
(-2.61%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -3.82 Million USD | 16.16% |
| 2022 | -4.56 Million USD | 62.23% |
| 2021 | -12.07 Million USD | -76.84% |
| 2020 | -6.82 Million USD | 9.21% |
| 2019 | -7.52 Million USD | 4.66% |
| 2018 | -7.88 Million USD | 75.74% |
| 2017 | -32.52 Million USD | 37.27% |
| 2016 | -51.84 Million USD | 23.44% |
| 2015 | -67.71 Million USD | 1.37% |
| 2014 | -68.65 Million USD | -148.81% |
| 2013 | -27.59 Million USD | -15.85% |
| 2012 | -23.81 Million USD | -5.14% |
| 2011 | -22.65 Million USD | -35.24% |
| 2010 | -16.75 Million USD | -119.11% |
| 2009 | -7.64 Million USD | 67.84% |
| 2008 | -23.76 Million USD | 10.17% |
| 2007 | -26.45 Million USD | -50.33% |
| 2006 | -17.6 Million USD | -13.23% |
| 2005 | -15.54 Million USD | 6.43% |
| 2004 | -16.61 Million USD | -47.21% |
| 2003 | -11.28 Million USD | -153.74% |
| 2002 | -4.44 Million USD | -377.52% |
| 2001 | -931.34 Thousand USD | 18.83% |
| 2000 | -1.14 Million USD | 92.85% |
| 1999 | -16.05 Million USD | -84.57% |
| 1998 | -8.7 Million USD | -19.18% |
| 1997 | -7.3 Million USD | -4.29% |
| 1996 | -7 Million USD | 26.32% |
| 1995 | -9.5 Million USD | -20.25% |
| 1994 | -7.9 Million USD | -139.39% |
| 1993 | -3.3 Million USD | -26.92% |
| 1992 | -2.6 Million USD | -218.18% |
| 1991 | 2.2 Million USD | 320.0% |
| 1990 | -1 Million USD | 76.74% |
| 1989 | -4.3 Million USD | 24.56% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -1.29 Million USD | -55.62% |
| 2024 Q1 | -831.9 Thousand USD | 5.69% |
| 2023 Q1 | -1.08 Million USD | -13.6% |
| 2023 Q4 | -882.11 Thousand USD | -4.97% |
| 2023 Q3 | -840.31 Thousand USD | 17.71% |
| 2023 Q2 | -1.02 Million USD | 5.45% |
| 2023 FY | -3.82 Million USD | 16.16% |
| 2022 FY | -4.56 Million USD | 62.23% |
| 2022 Q1 | -1.29 Million USD | 83.98% |
| 2022 Q2 | -1.14 Million USD | 11.32% |
| 2022 Q4 | -950.71 Thousand USD | 18.57% |
| 2022 Q3 | -1.16 Million USD | -1.7% |
| 2021 Q1 | -1.27 Million USD | 10.1% |
| 2021 Q3 | -1.53 Million USD | -29.75% |
| 2021 Q2 | -1.18 Million USD | 7.71% |
| 2021 Q4 | -8.08 Million USD | -427.42% |
| 2021 FY | -12.07 Million USD | -76.84% |
| 2020 Q2 | -1.34 Million USD | -9.36% |
| 2020 Q4 | -1.42 Million USD | 49.17% |
| 2020 Q1 | -1.22 Million USD | 58.46% |
| 2020 Q3 | -2.8 Million USD | -108.85% |
| 2020 FY | -6.82 Million USD | 9.21% |
| 2019 Q3 | -1.49 Million USD | -5.54% |
| 2019 FY | -7.52 Million USD | 4.66% |
| 2019 Q4 | -2.95 Million USD | -98.02% |
| 2019 Q2 | -1.41 Million USD | 15.23% |
| 2019 Q1 | -1.66 Million USD | -198.63% |
| 2018 Q2 | -2.42 Million USD | 36.83% |
| 2018 Q3 | -2.92 Million USD | -20.8% |
| 2018 Q4 | 1.68 Million USD | 157.7% |
| 2018 Q1 | -3.83 Million USD | 24.68% |
| 2018 FY | -7.88 Million USD | 75.74% |
| 2017 FY | -32.52 Million USD | 37.27% |
| 2017 Q2 | -9.2 Million USD | 4.99% |
| 2017 Q1 | -9.68 Million USD | -2.95% |
| 2017 Q3 | -8.17 Million USD | 11.21% |
| 2017 Q4 | -5.09 Million USD | 37.68% |
| 2016 Q3 | -11.79 Million USD | 35.98% |
| 2016 Q2 | -18.41 Million USD | -52.94% |
| 2016 Q4 | -9.41 Million USD | 20.18% |
| 2016 FY | -51.84 Million USD | 23.44% |
| 2016 Q1 | -12.04 Million USD | 47.36% |
| 2015 Q1 | -13.82 Million USD | -10.04% |
| 2015 Q4 | -22.87 Million USD | -61.39% |
| 2015 FY | -67.71 Million USD | 1.37% |
| 2015 Q2 | -16.63 Million USD | -20.36% |
| 2015 Q3 | -14.17 Million USD | 14.8% |
| 2014 FY | -68.65 Million USD | -148.81% |
| 2014 Q4 | -12.56 Million USD | 38.36% |
| 2014 Q3 | -20.37 Million USD | -87.49% |
| 2014 Q2 | -10.86 Million USD | 56.21% |
| 2014 Q1 | -24.82 Million USD | -143.59% |
| 2013 Q3 | -2.02 Million USD | 78.35% |
| 2013 Q2 | -9.33 Million USD | -220.59% |
| 2013 Q4 | -10.19 Million USD | -404.38% |
| 2013 Q1 | -2.91 Million USD | 78.84% |
| 2013 FY | -27.59 Million USD | -15.85% |
| 2012 Q3 | -4.88 Million USD | -2.29% |
| 2012 FY | -23.81 Million USD | -5.14% |
| 2012 Q4 | -13.75 Million USD | -181.44% |
| 2012 Q1 | -6.31 Million USD | 9.29% |
| 2012 Q2 | -4.77 Million USD | 24.35% |
| 2011 Q3 | -4.95 Million USD | -31.78% |
| 2011 FY | -22.65 Million USD | -35.24% |
| 2011 Q4 | -6.96 Million USD | -40.41% |
| 2011 Q1 | -6.87 Million USD | -207.65% |
| 2011 Q2 | -3.76 Million USD | 45.22% |
| 2010 FY | -16.75 Million USD | -119.11% |
| 2010 Q1 | -4.69 Million USD | -45.21% |
| 2010 Q4 | -2.23 Million USD | 52.42% |
| 2010 Q2 | -5.13 Million USD | -9.43% |
| 2010 Q3 | -4.69 Million USD | 8.57% |
| 2009 Q4 | -3.23 Million USD | -264.58% |
| 2009 Q2 | -2.32 Million USD | 42.49% |
| 2009 FY | -7.64 Million USD | 67.84% |
| 2009 Q1 | -4.04 Million USD | -12.26% |
| 2009 Q3 | 1.96 Million USD | 184.3% |
| 2008 Q2 | -3.97 Million USD | 27.47% |
| 2008 FY | -23.76 Million USD | 10.17% |
| 2008 Q4 | -3.6 Million USD | 66.3% |
| 2008 Q3 | -10.7 Million USD | -169.06% |
| 2008 Q1 | -5.48 Million USD | 25.67% |
| 2007 Q4 | -7.37 Million USD | -33.41% |
| 2007 FY | -26.45 Million USD | -50.33% |
| 2007 Q1 | -4.93 Million USD | -8.22% |
| 2007 Q2 | -8.39 Million USD | -70.23% |
| 2007 Q3 | -5.53 Million USD | 34.11% |
| 2006 Q4 | -4.55 Million USD | -45.64% |
| 2006 Q2 | -5.64 Million USD | -32.02% |
| 2006 Q3 | -3.12 Million USD | 44.56% |
| 2006 Q1 | -4.27 Million USD | -12.16% |
| 2006 FY | -17.6 Million USD | -13.23% |
| 2005 Q4 | -3.81 Million USD | -7.86% |
| 2005 Q3 | -3.53 Million USD | 23.08% |
| 2005 Q2 | -4.59 Million USD | -27.3% |
| 2005 Q1 | -3.6 Million USD | 37.96% |
| 2005 FY | -15.54 Million USD | 6.43% |
| 2004 Q1 | -3.83 Million USD | -44.09% |
| 2004 Q4 | -5.81 Million USD | -103.82% |
| 2004 Q2 | -4.11 Million USD | -7.3% |
| 2004 Q3 | -2.85 Million USD | 30.61% |
| 2004 FY | -16.61 Million USD | -47.21% |
| 2003 Q1 | -843.18 Thousand USD | -438.57% |
| 2003 FY | -11.28 Million USD | -153.74% |
| 2003 Q4 | -2.65 Million USD | 5.78% |
| 2003 Q3 | -2.82 Million USD | 43.08% |
| 2003 Q2 | -4.95 Million USD | -488.14% |
| 2002 Q3 | -2.35 Million USD | -133.67% |
| 2002 Q2 | -1 Million USD | -461.26% |
| 2002 Q1 | -179.24 Thousand USD | -106.21% |
| 2002 Q4 | 249.04 Thousand USD | 110.59% |
| 2002 FY | -4.44 Million USD | -377.52% |
| 2001 Q3 | -1.13 Million USD | 6.67% |
| 2001 Q1 | -1.15 Million USD | -162.73% |
| 2001 Q4 | 2.88 Million USD | 353.39% |
| 2001 FY | -931.34 Thousand USD | 18.83% |
| 2001 Q2 | -1.21 Million USD | -5.38% |
| 2000 Q3 | -842.04 Thousand USD | 12.28% |
| 2000 Q1 | -1.15 Million USD | 73.6% |
| 2000 FY | -1.14 Million USD | 92.85% |
| 2000 Q4 | 1.84 Million USD | 319.08% |
| 2000 Q2 | -959.88 Thousand USD | 16.57% |
| 1999 Q2 | -3 Million USD | 14.29% |
| 1999 FY | -16.05 Million USD | -84.57% |
| 1999 Q4 | -4.35 Million USD | 17.77% |
| 1999 Q3 | -5.3 Million USD | -76.67% |
| 1999 Q1 | -3.5 Million USD | -40.0% |
| 1998 Q4 | -2.5 Million USD | -19.05% |
| 1998 FY | -8.7 Million USD | -19.18% |
| 1998 Q1 | -1.8 Million USD | 52.63% |
| 1998 Q2 | -2.9 Million USD | -61.11% |
| 1998 Q3 | -2.1 Million USD | 27.59% |
| 1997 Q1 | -1.1 Million USD | 67.65% |
| 1997 Q4 | -3.8 Million USD | -192.31% |
| 1997 Q3 | -1.3 Million USD | 23.53% |
| 1997 Q2 | -1.7 Million USD | -54.55% |
| 1997 FY | -7.3 Million USD | -4.29% |
| 1996 Q3 | -1.1 Million USD | 8.33% |
| 1996 Q2 | -1.2 Million USD | 29.41% |
| 1996 Q1 | -1.7 Million USD | 51.43% |
| 1996 FY | -7 Million USD | 26.32% |
| 1996 Q4 | -3.4 Million USD | -209.09% |
| 1995 Q3 | -1.9 Million USD | 17.39% |
| 1995 Q2 | -2.3 Million USD | -21.05% |
| 1995 Q1 | -1.9 Million USD | 17.39% |
| 1995 FY | -9.5 Million USD | -20.25% |
| 1995 Q4 | -3.5 Million USD | -84.21% |
| 1994 Q1 | -1.7 Million USD | 19.05% |
| 1994 Q3 | -1.8 Million USD | 10.0% |
| 1994 Q2 | -2 Million USD | -17.65% |
| 1994 FY | -7.9 Million USD | -139.39% |
| 1994 Q4 | -2.3 Million USD | -27.78% |
| 1993 Q3 | -900 Thousand USD | -350.0% |
| 1993 Q1 | 100 Thousand USD | 108.33% |
| 1993 Q2 | -200 Thousand USD | -300.0% |
| 1993 Q4 | -2.1 Million USD | -133.33% |
| 1993 FY | -3.3 Million USD | -26.92% |
| 1992 Q4 | -1.2 Million USD | -50.0% |
| 1992 Q3 | -800 Thousand USD | -60.0% |
| 1992 Q2 | -500 Thousand USD | -25.0% |
| 1992 Q1 | -400 Thousand USD | 20.0% |
| 1992 FY | -2.6 Million USD | -218.18% |
| 1991 FY | 2.2 Million USD | 320.0% |
| 1991 Q4 | -500 Thousand USD | -150.0% |
| 1991 Q1 | 600 Thousand USD | 300.0% |
| 1991 Q2 | 1.1 Million USD | 83.33% |
| 1991 Q3 | 1 Million USD | -9.09% |
| 1990 Q4 | -300 Thousand USD | -200.0% |
| 1990 Q3 | -100 Thousand USD | 0.0% |
| 1990 Q1 | -500 Thousand USD | -150.0% |
| 1990 Q2 | - USD | 100.0% |
| 1990 FY | -1 Million USD | 76.74% |
| 1989 FY | -4.3 Million USD | 24.56% |
| 1989 Q3 | -600 Thousand USD | -700.0% |
| 1989 Q2 | 100 Thousand USD | 0.0% |
| 1989 Q1 | 100 Thousand USD | 101.59% |
| 1989 Q4 | -200 Thousand USD | 66.67% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | -186.321% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 24.202% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 78.576% |
| Nascent Biotech, Inc. | -2.22 Million USD | -71.472% |
| Rebus Holdings, Inc. | -664 Thousand USD | -475.847% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 104.671% |
| Qrons Inc. | -643.67 Thousand USD | -494.029% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -881.499% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 93.112% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -820.293% |
| Skye Bioscience, Inc. | -13.67 Million USD | 72.033% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 94.674% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 177.798% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -1360.927% |
| SQZ Biotechnologies Company | -75.82 Million USD | 94.957% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | -34.138% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -148.926% |
| Mesoblast Limited | -84.14 Million USD | 95.456% |
| Marizyme, Inc. | -34.08 Million USD | 88.783% |
| Genus plc | 6.4 Million USD | 159.744% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 139.247% |
| Pharming Group N.V. | -4.87 Million USD | 21.64% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -92.483% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -310.533% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 54.208% |
| ContraFect Corporation | -56.88 Million USD | 93.279% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 16.051% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -172.728% |
| IMV Inc. | -38.67 Million USD | 90.113% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | -38.999% |
| MultiCell Technologies, Inc. | -722.81 USD | -528894.618% |
| ONE Bio Corp. | 13.68 Million USD | 127.947% |
| Accustem Sciences Inc. | -3.74 Million USD | -2.061% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 93.518% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | -691.539% |
| Q BioMed Inc. | -3.44 Million USD | -10.971% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 208.012% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | -45.522% |
| Biomind Labs Inc. | -1 Million USD | -278.726% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 93.044% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | -31.792% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 42.485% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -105.089% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -12665.845% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 75.906% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -97.848% |
| GB Sciences, Inc. | -1.42 Million USD | -169.173% |
| Alpha Cognition Inc. | -9.7 Million USD | 60.604% |
| HST Global, Inc. | -140.9 Thousand USD | -2613.581% |
| CSL Limited | 3.7 Billion USD | 100.103% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -239.906% |
| Halberd Corporation | -75.05 Thousand USD | -4994.771% |
| Enzolytics Inc. | -2.14 Million USD | -77.942% |
| Agentix Corp. | -1.37 Million USD | -178.74% |
| Resverlogix Corp. | -12.74 Million USD | 70.008% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | -20.685% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | 99.1% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -266.248% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | -30.971% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -142.1% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | -12.295% |
| AVAX Technologies, Inc. | 6.69 Million USD | 157.13% |
| Zenith Capital Corp. | -8.94 Million USD | 57.244% |
| Genscript Biotech Corporation | -415.79 Million USD | 99.08% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -21848.373% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -55.728% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -2129.396% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -90.728% |
| Kadimastem Ltd | -3.04 Million USD | -25.767% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -288.559% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -204.429% |
| BioStem Technologies, Inc. | -7.77 Million USD | 50.847% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -2006.855% |
| Cell Source, Inc. | -4.32 Million USD | 11.6% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -456.609% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -456.609% |
| NovAccess Global Inc. | -2.46 Million USD | -55.006% |
| Affymax, Inc. | -15.04 Million USD | 74.587% |
| Itoco Inc. | -919.14 Thousand USD | -316.0% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 9.786% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -241.7% |
| Mobile Lads Corp. | -554.55 Thousand USD | -589.501% |
| CytoDyn Inc. | -18.05 Million USD | 78.826% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -15091.204% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -1637.396% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -577.08% |
| SYBLEU INC | -149.18 Thousand USD | -2463.096% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -110.515% |
| International Stem Cell Corporation | -663 Thousand USD | -476.716% |
| Bioxytran, Inc. | -3.82 Million USD | -0.091% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -7163.727% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -18698.555% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 89.457% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -136.318% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -419.631% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | -22.907% |
| Neutra Corp. | -229.48 Thousand USD | -1566.17% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 78.199% |
| PureTech Health plc | -146.19 Million USD | 97.385% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 82.208% |
| IXICO plc | -1.43 Million USD | -166.084% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 59.713% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 96.861% |
| CSL Limited | 3.81 Billion USD | 100.1% |
| Cellectis S.A. | -108.85 Million USD | 96.487% |